


CORPORATE OVERVIEW

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary rAAV gene-editing technology, GENESIS™, is industry leading. Using GENESIS™, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.

Horizon has applied GENESIS™ to create over 400 X-MAN™ cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modelling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease.


In addition to the X-MAN™ cell lines, Horizon provides GENESIS™ and X-MAN™ derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.

GENESIS and **X-MAN** are registered trademarks of Horizon Discovery Limited.




- Custom cellular disease model generation
- 400+ X-MAN™ models for licensing
- Derivative reagents


Horizon Discovery Services, Horizon Diagnostics and Horizon Bioproduction are trading divisions of Horizon Discovery Ltd.



- Cell biology
- Assay development
- Drug profiling






- Biomarker ID
- Functional assays
- Genetically-defined controls



- Leveraging CHO genome
- Optimising:
 - Selection
 - Expression
 - Glycosylation

NEW BUSINESS UNITS:

- COLTHERES / PREDICT / 4D CellFate
- SyntheTx, Senectus (Target ID)
- Discovery toolbox / alliances
- rAAV Centres of Excellence

HIGHLIGHTS IN 2011 INCLUDE:

- Top-line revenue growth at greater than 100% for the fourth consecutive year to \$7.5M with a 5th year projected for 2012
- Grown from 25 to 70 FTEs housed in state of art 20,000 sq. ft. facility in Cambridge, UK
- Major milestone achieved with a top pharmaceutical partner, releasing £6M committed revenue over 4 years
- Award of €2.2M (\$3.2M) grant funding from The Seventh Framework Programme for COLTHERES & 4D CellFate Consortia
- Establishment of the US National Institutes of Health (NCI & NHGRI) as an rAAV human gene-editing Centre of Excellence
- Entering into a long-term technology development and commercialization agreement with Promega Corporation
- Collaboration with University of Washington to apply rAAV gene editing in inducible human pluripotent stem cells




CONTACT DETAILS: Darrin Disley | Chief Executive Officer
T: +44 (0) 1223 655 580 | d.disley@horizondiscovery.com

MEDIA ENQUIRIES: Lorna Cuddon | Zyme Communications Ltd.
T: +44 (0)7811 996 942 | lorna.cuddon@zymecommunications.com

Horizon Discovery Ltd.
7100 Cambridge Research Park
Waterbeach, Cambridge
CB25 9TL, United Kingdom
Tel: +44 (0) 1223 655 580 Fax: +44 (0) 1223 655 581
E-mail: info@horizondiscovery.com
Web: www.horizondiscovery.com



Homologous recombination-mediated human gene-editing platform exploiting rAAV targeting vectors



Patient-relevant isogenic somatic models of human genetic diseases